| Ticker: AXG | ||
| Exchange: American Stock Exchange | Bermuda | |
| Industry: Manufacturing |
| Type of Shares: | American Depositary Receipts | Filing Date: | 10/30/96 | |
| U.S. Shares: | 4,600,000 | Offer Date: | 11/19/96 | |
| Non-U.S. Shares: | 0 | Filing Price: | - | |
| Primary Shares: | 4,600,000 | Offer Price: | $18.00 | |
| Secondary Shares: | 0 | Gross Spread: | $1.17 | |
| Offering Amount: | Selling: | $0.60 | ||
| Expenses: | - | Reallowance: | $0.00 | |
| Shares Out After: | - |
| Manager | Tier | Phone |
| Merrill Lynch & Co. | Lead Manager | (212) 449-4600 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| Revenue: | Assets: | ||||
| Net Income: | Liabilities: | ||||
| EPS: | Equity: | ||||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a world leader in the development of controlled-absorption drug delivery systems. As a result of its acquisition of Athena in July 1996, the company is an integrated drug delivery and biopharmaceutical company with expanded capabilities in the discovery, development and marketing of treatments for diseases or conditions of the central nervous system. The Athena Acquisition added discovery, research, marketing, sales and distribution capabilities to the company's expertise in drug delivery systems. The company manufactures, markets and licenses to clients drug products based on controlled absorption drug delivery systems. The company's drug delivery technologies are designed to improve and control the absorption and utilization by the human body of active pharmaceutical compounds, allowing these compounds to be administered less frequently, with reduced side effects and/or in reduced dosages. In addition to providing the potential for increasing the medical benefits and efficacy of active drug compounds, the company's drug delivery systems provide its client pharmaceutical companies with the opportunity to improve the commercial prospects for existing drugs. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.